The EPO published application EP4314061A1 for multispecific antibodies targeting cancer cells, filed by Merus N.V. The antibodies are classified under IPC C07K 16/28 (immunoglobulins, specifically antibodies for cancer treatment, A61P 35/00). The publication includes designation for all 35 European Patent Convention contracting states including Germany, France, UK, Italy, Spain, and others.

This is a routine patent publication with no compliance requirements or deadlines for third parties. Patent applicants and prosecution counsel should monitor the European Patent Register for subsequent examination proceedings. No action is required from generic pharmaceutical or biotechnology companies unless they are pursuing similar multispecific antibody technologies.